Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
..."we do not anticipate generic manufacturers selling the product in the near future”
Glad to see the Oxy filing this morning. Better late than never...
Dead wrong, anyone close to the pharma industry knows billions are flushed away in products that simply don't work. Decent pharma just know what the definition of "sunk cost" means and know when to stop.
SequestOx isn't going anywhere anytime soon. It is shelved until proven otherwise. Brick wall hit scrambling to find any sort of solution.
Purdue hitting the newswire again yesterday:
http://abcnews.go.com/Health/wireStory/city-asks-judge-case-oxycontin-maker-proceed-49941691
Except the CEO has zero credibility. He makes valiant efforts, but can't fully execute.
Will he be able to rebuild credibility? Possible, but not probable. Proof speaks louder than conjecture & fictitious/unrealistic market sizes.
We'll see soon enough.
It is forward looking only when there is credibility and solid evidence of future measurable benefit.
With professionals or the sloppy work Elite is doing? Take your pick.
The level at which they bring in isn't considered any meaningful revenue. Immaterial and rounding error in magnitude at any normal pharma company. Pure pittance.
What good is manufacturing drugs that don't sell? Oh yeah, to build up inventory that they will one day. Lol
Yes, precisely. Off the backs of shareholders. He isn't paid in cash. Lol
Yes, precisely. Off the backs of shareholders. He isn't paid in cash. Lol
And when was the last time they bought? Are you also saying the CEO isn't paid cash anymore?
Didn't see that one, but clearly false.
For real? CEO has stated this is the norm in the industry. The question becomes whether tiny Elite can handle the legal barrage they will certainly be getting from Purdue. Forgone conclusion, not "if".
No doubt that if these get approved (after expensive legal battle for Oxy) that these could be good revenue streams for Elite to dust itself off and get on its feet.
If Elite doesn't get a decent sales partner or worse, tries to fly solo, the PPS will tank and stays a "show me the results" stock with little to no forward multiple valuation benefit.
Well, the PPS has gone nowhere but down recently. I wonder why?!
Meh, a few pennies. No trust back then, no trust now in management either. Same old story with OTC stocks.
Happy to hear you are virtually unscathed and able to help those in need.
It is pretty darn close as it is.
Going it alone will destroy any potential incremental sales. Too many small companies try this route and become completely ruined. Building a skilled sales force is much more complex and costly than small companies can take on.
If Elite does go this route, I wouldn't be surprised as it would just continue to validate the CEO's junior varsity caliber.
Would be...if it was bioequivalent. But it isn't. Lol
Which pharmacy shelf is it on? Precisely.
We have no idea how close it actually was. No details were given. We know first results failed per FDA standards and more recent results would have too. End of story.
Here comes Nasrat the closer, to hammer the coffin with the final nail.
The company didn't resubmit because the results of the BE absolutely sucked for the second time. Had they resubmitted they would have received another CRL. Pesky facts...
What about a 4th CRL? LOL
Hiring of consultants means squat. They are searching for an answer. Doesn't mean one exists. Companies hire consultants all the time that add zero value. Similar to bringing on Eugene to help with the initial SequestOx submission. We all know how that worked out...CRL.
Love how all other facts are neglected and ignored regarding the mighty leader that can't execute jack squat.
SequestOx is dead for now.
SequestOx has failed twice. Not going anywhere anytime soon. Perhaps that changes in a few years. Current revenues were abysmal prior to Nasrat and still are.
Latest awesome deal: Trimipramine
Pure garbage.
Anything forward looking is not a fact. We all know how well the company does at predicting filings and results. What was that what was said? Oh yeah, no one will stop us, the FDA cannot stop us. Those are facts.
Those aren't facts. Those are forward looking statements protected under Safe Harbor. Not too long ago CEO stated filing at least one per quarter. Couldn't hit that spoken target within the first year. Very very sad.
Please don't bring up facts and reality here. They are irrelevant.
Haha! That is hilarious. It is, but hanging by a thread. I guess some like bragging rights on fractions of a penny.
The only shelf that matters is in the pharmacy so it can get to patients. It has made zero progress towards that. Attempts will be made, but nothing to prove otherwise. Nice try though.
Just dipped below 0.10. Great showcase of management trust.
CEO has diluted the hell out of this stock for several years. Lack of real execution has priced the company right, until CEO can get his poop in a group and get something of tangible market value executed.
Two strikes so far. 3 is a trend...and a strikeout.
Elite is going to file way before the end of the quarter? It was expected months ago, never happened. I guess "way before" is relative. With only a couple weeks left in the quarter, there's still a chance. Lol
RSI is a historical calculation. It ignores the fact that this is the new norm. Fail after fail will create this to be the normalized RSI over time. Even if they get Perc approval (hopefully they do) going it alone will make things worse for the company's stock and outlook. This company's ability to execute well against stated goals is extremely challenged and has decimated any credibility.
I just came back from an IR conference and the one thing they nailed time and time again is the importance of credibility.
That is great that they slapped the new partner's name on this, but there is nothing new here.
Nasrat said he would start marketing the company when he has solid proof to show. One CRL for each hand I guess is the proof he was looking for.